Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, explores the use of minimal residual disease (MRD) testing in the clinic for chronic lymphocytic leukemia (CLL) patients, and its use in determining the endpoint for treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
